ATE114112T1 - Aerosolzubereitung, die beclometason 17,21- dipropionat enthält. - Google Patents

Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.

Info

Publication number
ATE114112T1
ATE114112T1 AT92900942T AT92900942T ATE114112T1 AT E114112 T1 ATE114112 T1 AT E114112T1 AT 92900942 T AT92900942 T AT 92900942T AT 92900942 T AT92900942 T AT 92900942T AT E114112 T1 ATE114112 T1 AT E114112T1
Authority
AT
Austria
Prior art keywords
dipropionate
preparation containing
aerosol preparation
beclometasone
containing beclometasone
Prior art date
Application number
AT92900942T
Other languages
English (en)
Inventor
Robert K Schultz
David W Schultz
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24400688&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE114112(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Application granted granted Critical
Publication of ATE114112T1 publication Critical patent/ATE114112T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT92900942T 1990-10-18 1991-10-09 Aerosolzubereitung, die beclometason 17,21- dipropionat enthält. ATE114112T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59969490A 1990-10-18 1990-10-18

Publications (1)

Publication Number Publication Date
ATE114112T1 true ATE114112T1 (de) 1994-12-15

Family

ID=24400688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92900942T ATE114112T1 (de) 1990-10-18 1991-10-09 Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.

Country Status (12)

Country Link
EP (1) EP0553298B1 (de)
JP (2) JP2769925B2 (de)
AT (1) ATE114112T1 (de)
AU (1) AU658854B2 (de)
BR (1) BR1100339A (de)
CA (1) CA2094266C (de)
DE (1) DE69105212T2 (de)
DK (1) DK0553298T3 (de)
ES (1) ES2064160T3 (de)
HK (1) HK130397A (de)
NZ (1) NZ240237A (de)
WO (1) WO1992006675A1 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
DE4123663A1 (de) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Aerosol-zubereitung und verwendung eines treibmittels dafuer
DE69227257T2 (de) 1991-12-12 1999-03-25 Glaxo Group Ltd Arzneimittel
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
DE69205177T2 (de) * 1991-12-12 1996-03-21 Glaxo Group Ltd., Greenford, Middlesex Pharmazeutische Aerosolformulierung.
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
US5833950A (en) * 1992-07-31 1998-11-10 Glaxo Group Limited Aerosol formulations containing beclomethasone dipropionate-1, 1, 1, 2-tetrafluoroethane solvate
US5593661A (en) * 1993-03-29 1997-01-14 Henry; Richard A. Lidocaine aerosol anaesthetic
DE69424181T2 (de) * 1993-12-20 2000-10-19 Minnesota Mining And Mfg. Co., Saint Paul Flunisolide aerosolformulierungen
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
IL122752A (en) 1995-06-27 2001-07-24 Boehringer Ingelheim Kg Stable preparations for creating propellant-free sprays
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
JPH1067655A (ja) * 1996-08-23 1998-03-10 Nippon Hoechst Marion Roussel Kk 喘息治療用エアゾール剤
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
ES2244008T3 (es) * 1996-12-04 2005-12-01 Link Products Limited Composiciones farmaceuticas y dispositivos para su administracion.
US6120752A (en) * 1997-05-21 2000-09-19 3M Innovative Properties Company Medicinal aerosol products containing formulations of ciclesonide and related steroids
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
GB2326334A (en) † 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
US6264923B1 (en) 1998-05-13 2001-07-24 3M Innovative Properties Company Medicinal aerosol formulation of ciclesonide and related compounds
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
FR2798290B1 (fr) 1999-09-11 2003-09-12 Glaxo Group Ltd Formulation pharmaceutique de propionate de fluticasone
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
FR2813877B1 (fr) 2000-09-11 2002-12-06 Cezus Cie Europ Du Zirconium Procede de separation de metaux tels que le zirconium et l'hafnium
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
EP1340503A1 (de) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Lösung Aerosol Formulierung von Estern von 3,17-dihydroxy Oestratrien-Derivaten zur Lungenverabreichung
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
CA2489865C (en) 2002-06-25 2012-05-08 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
AUPS317302A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Metastable pharmaceutical compositions
CA2528479A1 (en) 2003-06-13 2004-12-23 Altana Pharma Ag Formoterol and ciclesonide combination
PL1670482T5 (pl) 2003-09-16 2022-10-03 Covis Pharma Gmbh Zastosowanie cyklezonidu w leczeniu chorób układu oddechowego
CA2677838C (en) 2007-02-11 2017-08-01 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
US8652443B2 (en) 2008-02-14 2014-02-18 Precision Dermatology, Inc. Foamable microemulsion compositions for topical administration
AR079451A1 (es) 2009-12-18 2012-01-25 Nycomed Gmbh Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina
EP2627386B1 (de) 2010-10-12 2015-04-22 Ivax Pharmaceuticals Ireland Nasensprayvorrichtung
US20140113877A1 (en) 2011-06-15 2014-04-24 Takeda Gmbh Novel 3,4,4a,10b-tetrahydro-1h-thiopyrano[4,3-c] isoquinoline compounds
WO2012171900A1 (en) 2011-06-17 2012-12-20 Nycomed Gmbh Novel phthalazinone-pyrrolopyrimidinecarboxamide derivatives
AU2012296880A1 (en) * 2011-08-18 2014-03-27 Astrazeneca Ab Pharmaceutical aerosol product for administration by oral or nasal inhalation
BR112014006597A2 (pt) * 2011-09-20 2017-03-28 Sergeant's Pet Care Products Inc composições de interomônio e seu uso para modificar comportamento em espécies de vertebrado diferentes
US9480688B2 (en) 2011-09-20 2016-11-01 Sergeant's Pet Care Products, Inc. Pheromone compositions and their use to modify behavior in different vertebrate species
WO2018069210A1 (en) 2016-10-10 2018-04-19 Takeda Gmbh Tetrahydrofuro[3,4-c]isoquinolines as inhibitors of pde4
US20200268706A1 (en) * 2017-02-27 2020-08-27 Gregory LEVITIN Combination of furosemide and steroids and application system therefor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
IL97065A (en) * 1990-02-02 1994-01-25 Fisons Plc Repellent preparations for aerosol
DE4003272A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen

Also Published As

Publication number Publication date
NZ240237A (en) 1994-06-27
WO1992006675A1 (en) 1992-04-30
EP0553298A1 (de) 1993-08-04
EP0553298B1 (de) 1994-11-17
CA2094266A1 (fr) 1992-04-19
JPH06501710A (ja) 1994-02-24
BR1100339A (pt) 2000-07-18
CA2094266C (en) 1999-06-01
DK0553298T3 (da) 1995-04-18
ES2064160T3 (es) 1995-01-16
AU658854B2 (en) 1995-05-04
HK130397A (en) 1997-09-19
JPH10182467A (ja) 1998-07-07
AU9087391A (en) 1992-05-20
DE69105212D1 (de) 1994-12-22
JP2769925B2 (ja) 1998-06-25
DE69105212T2 (de) 1995-03-23

Similar Documents

Publication Publication Date Title
ATE114112T1 (de) Aerosolzubereitung, die beclometason 17,21- dipropionat enthält.
DE69231992D1 (de) Fluorchlorkohlenwasserstofffreie Aerosolformulierungen
YU59192A (sh) Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
AU5306486A (en) Drug-containing chlorofluorocarbon aerosol propellent formulations
CA2381329A1 (en) Medicaments
DK0625046T3 (da) Farmaceutiske aerosolformuleringer indeholdende beclomethasondipropionat
CA2178473A1 (en) Flunisolide aerosol formulations
NO990454D0 (no) Aerosol-materiale
NO980858D0 (no) Farmasöytiske preparater og anordninger for administrering derav
NO910186L (no) Fremgangsmaate for fremstilling av et oralt inhalerbart, farmasoeytisk atropin-salbutamol-aerosolpreparat.
AU6326094A (en) New medicament aerosol formulation based on fusafungine, a process for its preparation and pharmaceutical compositions containing it
NL7901103A (nl) 1,1-digesubstitueerde octahydroindool 2,3-a chinoli- zinen, farmaceutisch aanvaardbare zouten daarvan; werk- wijze voor de bereiding van deze verbindingen, farmaceutische preparaten waarin zich deze verbindingen bevinden, met vaatverwijdende eigenschappen.
MX9707238A (es) Formulaciones en aerosol de butixocort.
CA2141039A1 (en) Surfactant free aerosol formulations containing beclomethasone dipropionate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification